Guardant Health Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and Prime Medicine, Inc. (PRME)
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $34
Guardant Health's Strong Q2 Performance and Promising Pipeline Merit Buy Rating With Raised Target
Guardant Health Price Target Raised to $37.00/Share From $28.00 by Craig-Hallum
Guardant Health Analyst Ratings
Guardant Health's Strong Q2 Leads to Increased Price Target and Buy Rating
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
Guardant Health (GH) Gets a Buy From Craig-Hallum
BTIG Sticks to Their Buy Rating for Guardant Health (GH)
Buy Rating Affirmed for Guardant Health Amid Positive FDA Approval and Growth Prospects
Guardant Health Analyst Ratings
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40
CCORF Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42
TD Cowen Sticks to Their Buy Rating for Guardant Health (GH)
TD Cowen Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $41
Guardant Health Poised for Growth: Buy Rating Affirmed Amid FDA Approval and Strategic Expansions
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40
Guardant Health Analyst Ratings
No Data